Endocrine Abstracts

Background and aims: To describe the characteristics of patients with non-controlled type 2 diabetes mellitus with liraglutide treatment.

Materials and methods: Retrospective descriptive study. 85 outpatients (women 49, ages 18–86 years old with non-controlled type 2 diabetes mellitus were evaluated between July 2013 and March 2014 and received treatment with liraglutide 1.8 mg Q18/day (0.6 mg Q18 during the first week, 1.2 mg Q18 during the send week and 1.8 mg during the third week and the rest of the treatment). Age, sex, diagnosis time, weight, HbA1c, fasting glucose, systolic and diastolic blood pressure, pharmacological treatment during 6 months were extracted for analysis.

Results: Patients treated with liraglutide 1.8 mg as monotherapy or in conjunction with a therapeutic scheme decreased HbA1c values at 3 and 6 months (1.02% 95% CI ±0.93 P<0.0001 y 2.08% 95% CI ±0.8 P<0.0001); fasting glucose at 3 and 6 months (37 mg/dl 95% CI±33 P<0.0001 y 68 mg/dl 95% CI±26 P<0.0001); weight at 3 and 6 months (3 kg 95% CI±10 P<0.0001 y 5 kg 95% CI±10 P<0.0001); SBP at 3 and 6 months (9 mmHg 95% CI±15 P<0.0001 y 16 mmHg 95% CI±16 P<0.0001); DBP at 3 and 6 months (3 mmHg 95% CI±6 P<0.0001 y 6 mmHg 95% CI±6 P<0.002). 40% of patients reached HbA1c <7.0; 20% reduction of HbA1c, 39% reduction in fasting blood glucose, 6% reduction in mean weight (1–18%, 1–12 kg), 95% reached SBP <140 mmHg; 100% reached DBP <90 mmHg. Reported adverse events during treatment were nausea (27%), abdominal pain (18%), hypoglycaemia (14%), diarrhoea (9%), respiratory symptoms (7%). Metformin was present in 65% cases of nausea, 55% cases of diarrhoea and 43% of cases of abdominal pain. No fatal adverse events occurred.

Conclusion: Patients treated with liraglutide 1.8 mgQ18/day in monotherapy or in conjunction with a therapeutic scheme showed a decrease in HbA1c, fasting glucose, weight, SBP, DBP during a 6 month treatment.